抗HER2治疗与放疗同步给药:系统综述
该系统综述检索Medline、Embase和Cochrane数据库,汇总抗HER2药物(曲妥珠单抗、帕妥珠单抗、拉帕替尼、T-DM1)与放疗同步使用的临床及临床前数据。曲妥珠单抗联合放疗研究最多,重点在心脏毒性;拉帕替尼联合放疗主要集中于HER2阳性乳腺癌脑转移。帕妥珠单抗与T-DM1数据匮乏,多为病例报告。
要点
- 曲妥珠单抗与放疗同步的研究最多,关注点为心脏毒性
- 拉帕替尼联合放疗的研究集中于HER2阳性乳腺癌脑转移
- 帕妥珠单抗和T-DM1与放疗同步的数据主要为病例报告
核心结论
- 由于文献数据异质性大,目前难以就抗HER2治疗同步放疗的毒性或疗效得出可靠结论,需更大规模和长期随访确认。
- 综述未报告严重不良事件,毒性谱似乎可控。
研究设计与样本
- 系统综述,检索Medline、Embase和Cochrane数据库中抗HER2治疗(曲妥珠单抗、帕妥珠单抗、拉帕替尼、T-DM1)与放疗同步联合的临床前及临床相关文章。
主要发现
- 曲妥珠单抗与放疗联合的研究最多,重点关注心脏毒性。
- 拉帕替尼与放疗联合的研究主要在HER2阳性乳腺癌脑转移背景下进行。
- 帕妥珠单抗和T-DM1与放疗联合的数据匮乏,主要为病例报告。
临床怎么用
- 同步抗HER2治疗与放疗时需关注心脏毒性,尤其是曲妥珠单抗联合方案。
- HER2阳性乳腺癌脑转移可参考拉帕替尼联合放疗的研究数据。
- 帕妥珠单抗和T-DM1同步放疗的证据有限,决策需个体化。
局限性
- 文献数据异质性大,难以得出关于毒性或疗效的可靠结论。
- 帕妥珠单抗和T-DM1相关数据主要为病例报告,证据等级低。
- 结论需更大规模和长期随访研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over the past few years, anti-HER2 targeted therapies have proven to be a key treatment in the management of human epidermal growth receptor 2 (HER2)-positive breast cancers, as well as gastrointestinal tract tumors and head and neck tumors. Anti-HER2 therapies administered alone or in combination with chemotherapy have been extensively studied, but only limited robust data are available concerning the safety and efficacy of anti-HER2 molecules in combination with radiotherapy. METHODS: We searched on Medline, Embase and Cochrane databases the articles providing data on the concomitant association between the antiHER2 therapies used in clinical practice (trastuzumab, pertuzumab, lapatinib and T-DM1) with radiotherapy. The articles were selected according to their pre-clinical and clinical relevance. RESULTS: The trastuzumab-irradiation combination is the most studied, with a focus on the cardiac toxicity. The combination of lapatinib-irradiation was particularly studied in the context of cerebral metastases of HER2-positive breast cancer. The data on pertuzumab and T-DM1 were poor and are mainly case reports. CONCLUSION: To date, reliable conclusions about the toxicity and/or efficacy of concomitant irradiation with anti-HER2 therapies are difficult to make due to the heterogeneity of the data in the literature and need to be confirmed on a larger scale and long term follow-up. Nevertheless, no serious adverse events are reported and the toxicity profile seems to be manageable.
引用
- Mignot F, Ajgal Z, Xu H, et al. Concurrent administration of anti-HER2 therapy and radiotherapy: Systematic review. Radiother Oncol. 2017. PMID: 28751231. doi:10.1016/j.radonc.2017.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。